Antiemetic Efficacy of High-Dose Dexamethasone in Induction Therapy in Acute Nonlymphocytic Leukemia
- PETER A. CASSILETH, M.D.;
- EDWARD J. LUSK, Ph.D.;
- SUSAN TORRI, R.N.; and
- STANTON L. GERSON, M.D.
Excerpt
Nausea and vomiting continue to be distressing side effects of cancer chemotherapy. We recently reported (1) a randomized, double-blind study in which a single 10-mg dose of intravenous dexamethasone markedly reduced the gastrointestinal side effects of mildly emetogenic chemotherapy for outpatients with breast cancer. We now report the safety and efficacy of repeated doses of dexamethasone in eliminating the nausea and vomiting of induction chemotherapy for patients with acute nonlymphocytic leukemia.
All patients included in the study were adults with acute nonlymphocytic leukemia (at diagnosis or on relapse) at the Hospital of the University of Pennsylvania and were treated with
This 100-word excerpt has been provided in the absence of an abstract.
Acknowledgments
ACKNOWLEDGMENTS: The authors thank Ms. Debora Bradt for preparation of the manuscript.
Article and Author Information
-
Grant support: in part by grant CA-16520 from the National Cancer Institute, and from Organon, Inc. , West Orange, New Jersey.
-
▸Requests for reprints should be addressed to Peter A. Cassileth, M.D.; Hematology-Oncology Section, Hospital of the University of Pennsylvania, 3400 Spruce Street; Philadelphia, PA 19104.
Most Read
